29 peer-reviewed studies · Evidence score: 8.5/10
Wei C et al. • Nutrients (2025)
There are various types of nattokinase preparations on the market, and consumers should choose regular products with high activity and purity, and pay attention to their safety and applicable population.
Dobre MZ et al. • International journal of molecular sciences (2025)
Given the variability in evidence and product quality, their use should be individualized, with further large-scale clinical trials needed to establish safety and efficacy.
Bernacka K et al. • Nutrients (2025)
Potential future studies focused on developing functional fermented foods and easy-to-use supplements based on fermented plant products are suggested.
Mahakalakar N et al. • Brain research (2025)
Furthermore, the study of NK on the cardiovascular system leads to certain assumptions, which include the impact on vasculature function and the ability to manage blood flow, which is the key featu...
Toussaint F et al. • Dermatologie (Heidelberg, Germany) (2025)
The Author(s), under exclusive licence to Springer Medizin Verlag GmbH, ein Teil von Springer Nature.
Granito M et al. • Expert review of cardiovascular therapy (2024)
Due to the fibrinolytic and antithrombotic activity of nattokinase, and more recently added to the anti-inflammatory and antioxidant effects, this enzyme can be used as a new adjuvant therapeutic strategy to mitigate inflammation and oxidative stress in NCDs, including CVD.
Muric M et al. • Biomolecules (2024)
By combining evidence from basic research with clinical findings, we aim to elucidate the comparative cardioprotective efficacy of these interventions and highlight their respective roles in modern cardiovascular care.
Sheng Y et al. • Food & function (2023)
Finally, the possible future directions focused on NK studies were proposed and provided suggestions for subsequent researchers.
Gasmi A et al. • Critical reviews in food science and nutrition (2022)
Moreover, the paper reviews the enzyme nattokinase's role in thrombotic prevention due to its fibrinolytic activity.
Yuan L et al. • Biomolecules (2022)
Finally, this review summarizes the clinical applications of nattokinase.
Abdul Rahim P et al. • Current pharmaceutical biotechnology (2022)
This review deals with the fibrinolytic enzymes, their mechanisms, sources, and their therapeutic potential.Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.
Weng Y et al. • International journal of molecular sciences (2017)
Opportunities for utilizing plant systems for the large-scale production of NK, or for the production of edible plants that can be used to provide oral delivery of NK without extraction and purification are also discussed.
Kumar SS et al. • Advances in experimental medicine and biology (2019)
Reported enzymes from various sources with potential to be used as cardiovascular therapeutic is also discussed here.
Wan R et al. • Current pharmaceutical design (2018)
This review will focus on the progress and current status in this research.Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.
Cai D et al. • World journal of microbiology & biotechnology (2017)
Finally, the prospect of microbial nattokinase production was also discussed regarding the recent progress, challenge, and trends in this field.
Kotb E • Biotechnology progress (2014)
This review is the first to cover all the natural and recombinant thrombolytic agents used in enzyme therapy.
Liu X et al. • Nutrients (2023)
However, it did not significantly affect serum TG, HDL-C, and CIMT.
Zhang K et al. • Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association (2026)
Six-month NK supplementation did not improve global cognition in asymptomatic intracranial/carotid stenosis patients.
Gallelli G et al. • Nutrients (2021)
Therefore, we can conclude that the use of nattokinase represents an efficient and safe treatment able to both prevent and treat patients with vascular diseases.
Hodis HN et al. • Clinical hemorheology and microcirculation (2021)
Results of this trial show that nattokinase supplementation has a null effect on subclinical atherosclerosis progression in healthy individuals at low risk for CVD.